Pulmonary delivery of cisplatin-hyaluronan conjugates via endotracheal instillation for the treatment of lung cancer
dc.contributor.author | Xie, Yumei | |
dc.contributor.author | Aillon, Kristin L. | |
dc.contributor.author | Cai, Shuang | |
dc.contributor.author | Christian, Jason M. | |
dc.contributor.author | Davies, Neal M. | |
dc.contributor.author | Berkland, Cory J. | |
dc.contributor.author | Forrest, M. Laird | |
dc.date.accessioned | 2017-03-14T20:29:13Z | |
dc.date.available | 2017-03-14T20:29:13Z | |
dc.date.issued | 2011-06-15 | |
dc.identifier.citation | Xie, Yumei, Kristin L. Aillon, Shuang Cai, Jason M. Christian, Neal M. Davies, Cory J. Berkland, and M. Laird Forrest. "Pulmonary Delivery of Cisplatin-hyaluronan Conjugates via Endotracheal Instillation for the Treatment of Lung Cancer." International Journal of Pharmaceutics 392.1-2 (2010): 156-63. | en_US |
dc.identifier.uri | http://hdl.handle.net/1808/23411 | |
dc.description.abstract | Cisplatin (CDDP) intravenous treatments suffer several dose-limiting toxicity issues. Hyaluronan (HA), a naturally occurring biopolymer in the interstitium, is primarily cleared by the lymphatic system. An alteration in input rate and administration route through pulmonary delivery of hyaluronan-cisplatin conjugate (HA-Pt) may increase local lung CDDP concentrations and decrease systemic toxicity.Sprague-Dawley rats were split into four groups: i.v. CDDP (3.5 mg/kg), i.v. HA-Pt conjugate (3.5 mg/kg equivalent CDDP), lung instillation CDDP and lung instillation HA-Pt conjugate. Total platinum level in the lungs of the HA-Pt lung instillation group was 5.7-fold and 1.2-fold higher than the CDDP intravenous group at 24 h and 96 h, respectively. A 1.1-fold increase of Pt accumulation in lung draining nodes for the HA-Pt lung instillation group was achieved at 24 h relative to the CDDP i.v. group. In the brain and kidneys, the CDDP i.v. group had higher tissue/plasma ratios compared to the HA-Pt lung instillation group. Augmented tissue distribution from CDDP i.v. could translate into enhanced tissue toxicity compared to the altered input rate and distribution of the intrapulmonary nanoformulation.In conclusion, a local pulmonary CDDP delivery system was developed with increased platinum concentration in the lungs and draining nodes compared to i.v. therapy. | en_US |
dc.publisher | Elsevier | en_US |
dc.rights | This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License 3.0 (CC BY-NC-ND 3.0 US), which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. | en_US |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/ | |
dc.subject | Cisplatin | en_US |
dc.subject | Hyaluronan | en_US |
dc.subject | Pharmacokinetics | en_US |
dc.subject | Pulmonary delivery | en_US |
dc.subject | Lung chemotherapeutics | en_US |
dc.title | Pulmonary delivery of cisplatin-hyaluronan conjugates via endotracheal instillation for the treatment of lung cancer | en_US |
dc.type | Article | en_US |
kusw.kuauthor | Berkland, Cory | |
kusw.kudepartment | Pharmaceutical Chemistry | en_US |
dc.identifier.doi | 10.1016/j.ijpharm.2010.03.058 | en_US |
kusw.oaversion | Scholarly/refereed, author accepted manuscript | en_US |
kusw.oapolicy | This item meets KU Open Access policy criteria. | en_US |
dc.rights.accessrights | openAccess |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as: This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License 3.0 (CC BY-NC-ND 3.0 US), which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.